# CTS-1027 in Interferon-Naive Hepatitis C Patients

> **NCT00925990** · PHASE2 · COMPLETED · sponsor: **Conatus Pharmaceuticals Inc.** · enrollment: 70 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** ribavirin
- **DRUG:** CTS-1027
- **DRUG:** Placebo for ribavirin

## Key facts

- **NCT ID:** NCT00925990
- **Lead sponsor:** Conatus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-05
- **Final completion:** 2010-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2012-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925990, "CTS-1027 in Interferon-Naive Hepatitis C Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00925990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*